# Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

> **NCT06666348** · PHASE1,PHASE2 · RECRUITING · sponsor: **St. Justine's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Pediatric Low-grade Glioma

## Interventions

- **DRUG:** Mirdametinib

## Key facts

- **NCT ID:** NCT06666348
- **Lead sponsor:** St. Justine's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-12
- **Primary completion:** 2030-04
- **Final completion:** 2033-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666348, "Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06666348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*